Volixibat

立即咨询

Volixibat

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1025216-57-2

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
50mg	电议
100mg	电议

产品名称

SHP626
LUM002

产品介绍

Volixibat (SHP626;LUM002) 是一种高选择性、低吸收、竞争性的顶端钠依赖性胆汁酸转运体(ASBT)抑制剂。Volixibat 有潜力用于非酒精性脂肪性肝炎 (NASH) 的研究。

生物活性

Volixibat (SHP626) is a highly selective, minimally absorbed, and competitiveapical sodium-dependent bile acid transporter(ASBT)inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)^[1]^[2].

体内研究
(In Vivo)

Volixibat (SHP626) (5-30 mg/kg; food intake; daily for 24 weeks) improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice^[1].

Animal Model:	Male Ldlr-/-.Leiden mice (high-fat diet, HFD)^[1]
Dosage:	5, 15, or 30 mg/kg
Administration:	Food intake; daily for 24 weeks
Result:	Significantly increased the total amount of bile acid in feces. Significantly attenuated the HFD-induced increase in hepatocyte hypertrophy, hepatic triglyceride and cholesteryl ester levels, and mesenteric white adipose tissue deposition at the highest dose. Non-alcoholic fatty liver disease activity score (NAS) was significantly lower in volixibat-treated mice than in the HFD controls.

Clinical Trial

分子量

805.95

Formula

C₃₈H₅₁N₃O₁₂S₂

CAS 号

1025216-57-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.